CRISPR-Cas9 deletion (CRISPR-del) is the leading approach for eliminating DNA from mammalian cells and underpins a variety of genome-editing applications. Target DNA, defined by a pair of double strand breaks (DSBs), is removed during non-homologous end-joining (NHEJ). However, the low efficiency of CRISPR-del results in laborious experiments and false negative results. Using an endogenous reporter system, we demonstrate that temporary inhibition of DNA-dependent protein kinase (DNA-PK) -an early step in NHEJ -yields up to 17-fold increase in DNA deletion. This is observed across diverse cell lines, gene delivery methods, commercial inhibitors and guide RNAs, including those that otherwise display negligible activity. Importantly, the method is compatible with pooled functional screens employing lentivirally-delivered guide RNAs. Thus, delaying the kinetics of NHEJ relative to DSB formation is a simple and effective means of enhancing CRISPR-deletion.
Introduction
CRISPR-Cas9 technology enables a variety of loss-of-function perturbations to study the functions of genomic elements in their natural context, and engineer natural and unnatural mutations [1] [2] [3] . One such application, CRISPR-deletion (CRISPR-del), is a means of permanently removing specific genomic fragments from 10 1 -10 6 base pairs 4 . This range has enabled researchers to investigate a wide variety of functional elements, including gene regulatory sequences [5] [6] [7] , non-coding RNAs [8] [9] [10] [11] [12] , and structural elements 13 . Similarly, engineered deletions can be used to model human mutations 14, 15 . CRISPR-del is readily scaled to high throughput screens, via pooled lentiviral libraries of thousands of paired single guide RNAs (sgRNAs) 16, 17 . This has been used to discover long noncoding RNAs (lncRNAs) regulating cancer cell proliferation 18, 19 and to map cis-regulatory regions of key protein-coding genes 20, 21 .
CRISPR-del employs a pair of CRISPR-Cas9 complexes to introduce double strand breaks (DSBs) at two sites flanking the target region. Thereafter it relies on the endogenous non-homologous end joining (NHEJ) process to repair the breaks so as to eject the intervening fragment [22] [23] [24] [25] . The two ends of target regions are defined by a pair of user-designed sgRNAs 26 . Paired sgRNAs may be delivered by transfection or viral transduction 17, 25 .
Pooled screens require that both sgRNAs are encoded in a single vector to ensure their simultaneous delivery, and are typically performed under conditions of low multiplicity-of-infection (MOI), where each cell carries a single lentiviral insertion 18, 20, 25, 27, 28 .
The principal drawback of CRISPR-del is the low efficiency with which targeted alleles are deleted. Studies on cultured cells typically report efficiencies in the range 0% -50% of alleles, and often <20% 29, 30 , similar to estimates from individual clones 4, 17, [24] [25] [26] . Indeed, a recent publication reported high variation in the efficiencies of paired sgRNA targeting the same region, including many that yielded negligible deletion 30 . Transfection typically yields greater efficiency than viral transduction, possibly due to higher sgRNA levels 32 , but is incompatible with pooled screening. Although megabase-scale deletions have been reported 33, 34 , deletion efficiency decreases with increasing target size 4 . Homozygous knockout clones may be isolated by screening hundreds of single cells, however this is slow and laborious, and resulting clones may not be representative of the general population 31 . More important than these practical costs, is the potential impact of low deletion rates on the ability to discern bona fide functional effects arising from a given mutation 30 . Non-performing sgRNA pairs are a particular problem for pooled CRISPR-del screens, where they reduce statistical power and lead to false negative results. To combat this, researchers are forced to increase the coverage of deletion constructs per target, resulting in lower candidate numbers and increased costs 35, 36 . Consequently, any method to improve CRISPR-del efficiency would streamline experiments and enable the discovery of presently-overlooked functional elements.
For other applications of CRISPR, most notably precise genome editing using homologous recombination (HR), substantial gains have been made editing efficiency 37 . Here, editing events are rare, and HR is the rate-limitingstep 38, 39 . The two principal strategies to boost efficiency are: (1) direct stimulation of homology directed repair (HDR) 37,40-42 ; (2) suppression of the competing NHEJ pathway at early stages through inhibition of Ku70/80 complex 37, 40, 43 or DNA-dependent protein kinase (DNA-PK) 37, 40, 44, 45 , or at late phases, via Ligase IV (LigIV) inhibition 37, 40, 46, 47 . To date, however, there are no reported methods for pharmacological enhancement of CRISPR-del.
Towards this aim, we consider the events necessary for successful deletion (Fig. 3 ). In the presence of two DSBs, NHEJ gives rise to successful deletion. For this to occur, the DSBs must occur on a timescale shorter than that required for NHEJ. Otherwise, the first DSB is repaired by NHEJ before the second can occur, and deletion will not take place. Furthermore, there is a high probability that the target protospacer or protospacer adjacent motif (PAM) is mutated during NHEJ, rendering it inaccessible to the sgRNA and precluding any subsequent deletion.
A prediction of this model, is that successful deletion can be promoted by extending the time over which DSBs persist without being repaired, and hence increasing the likelihood that both DSBs co-occur. In other words, we hypothesise that CRISPR-del may be improved by pharmacologically slowing the rate of NHEJ during the period while DSBs are taking place. Here, we show that inhibition of DNA-PK, an early step in NHEJ, indeed improves CRISPR-del efficiency, regardless of cell type, target region, sgRNA or inhibitory molecule, and represents a practical strategy for a variety of applications including pooled library screening.
Results

A quantitative endogenous reporter for CRISPR-del
To identify factors capable of improving CRISPR-del efficiency, we designed a gene-based reporter system: CRISPR Deletion Endogenous Reporter (CiDER). Such a system should be quantitative, sensitive, practical and able to closely model the CRISPR-del process by targeting endogenous genes rather than plasmids. We focussed on genes encoding cell-surface proteins, as they can be rapidly and sensitively detected by flow cytometry 48 . A number of candidates were considered with criteria of (1) non-essentiality for cell viability and proliferation [49] [50] [51] (https://depmap.org), (2) high expression in human cell lines 52 (http://www.proteinatlas.org), (3) lack of overlap with other genomic elements that could lead to false positive detection, and (4) availability of flowcytometry grade antibody. Consequently, we selected PLXND1 encoding the Plexin-D1 protein ( Supplementary   Fig. 1 ).
We conceived an experimental setup where only successful CRISPR-del leads to loss of PLXND1 expression, but unsuccessful events do not. In this scheme, the gene's first exon is targeted for deletion by a series of sgRNA pairs recognising the non-protein coding regions upstream (promoter) and downstream (first intron) ( Fig. 1a ).
Successful deletions of the first exon are expected to silence protein expression, but indels from individual sgRNAs do not affect the protein sequence directly and should not lead to silencing. Finally, we also designed sgRNAs that directly target the open reading frame (ORF), since these are expected to yield maximal protein silencing (designated positive control, P+).
We used flow cytometry to evaluate Plexin-D1 protein levels (Fig. 1b ). Positive control sgRNAs (P+) yielded approximately 90% knockout efficiency. We observed wide variability in the deletion efficiency of sgRNA pairs, from Pair1 (P1) displaying minimal efficacy, to the most efficient P4 yielding ~40% deletion. Therefore these paired sgRNAs achieve deletion efficiencies that are comparable to previous studies 4, 26 . Measured deletion rates were consistent across biological replicates (Fig. 1b) . The observed loss of Plexin-D1 was not due to large indels or disruption of gene regulatory elements at individual sgRNA target sites 53 , since control experiments with single sgRNAs showed no loss of Plexin-D1 ( Supplementary Fig. 2 ). In CiDER we have a reproducible and practical reporter of CRISPR-del at a range of efficiencies.
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Temporary inhibition of DNA-PK during DSB formation increases CRISPR-del efficiency
We hypothesized that temporarily inhibiting NHEJ during DSB formation would favour CRISPR-del, by increasing the chance that both DSBs will co-occur ( Fig. 3) . We tested DNA-PK, a DNA end-binding factor at the first step of NHEJ pathway, for which a number of small-molecule inhibitors are available 54 . We began by treating HeLa cells with the inhibitor M3814 (IC50=3nM) 45, 55, 56 at two concentrations (300 nM and 900 nM).
Importantly, cells constitutively expressing Cas9 were treated for an 18 hour time window, 4 hours after sgRNA expression plasmid delivery by transfection. Thus, DNA-PK was inhibited immediately before sgRNA expression. This resulted in improved deletion rates for all four sgRNA pairs, including a 17-fold increase for P1, which otherwise displays negligible deletion under normal conditions (Fig. 1c,e ).
We next asked whether other inhibitors of DNA-PK yield a similar effect. We treated cells with four other commercially-available molecules at a concentration of 10uM: KU57788 (IC50=14nM), NU7026 (IC50=230nM), LTURM34 (IC50=34nM) and DMNB (IC50=15uM) (Fig. 1f ). Each one yielded increases in CRISPR-del efficiency to varying degrees, correlating with published differences on the inhibition potency 57 . As expected based on previous literature, KU57788 gave the strongest effect 57 and DMNB gave the weakest effect, likely due to its high IC50.
We were curious whether improved deletion depends on inhibition specifically of DNA-PK, or more generally on NHEJ. To answer this, we used SCR7 pyrazine to inhibit another step in NHEJ, the final ligation by Ligase IV (LigIV). In contrast to DNA-PK, this treatment did not improve deletion efficiency ( Fig. 2a ). At this late stage, the NHEJ machinery (DNA-end binding and processing complex) is already maintaining together the free DNA ends. When LigIV activity is restored, it may be more likely that each single DSB is repaired independently, introducing small indels rather than favouring genomic deletion. Thus, CRISPR-del efficiency improvements depend specifically on inhibition of DNA-PK activity. Altogether, we have shown that pharmacological inhibition of NHEJ at the DNA-PK step yields enhanced deletion of PLXND1 reporter in HeLa cells.
Generality of deletion enhancement by DNA-PK inhibition
We next assessed whether this DNA-PK-inhibition is more generally effective across cell lines, genomic targets and sgRNA delivery modalities.
We began by replicating CiDER experiments in two widely-used cell lines, HCT116 and HEK293T 30, [58] [59] [60] (Fig.   2b ). Both have baseline CRISPR-del efficiency below HeLa, possibly due to weaker NHEJ activity 39 .
Nevertheless, DNA-PK inhibition enhanced deletion in both cell backgrounds.
All experiments so far involved a single target locus, assayed by flow cytometry. We next assessed whether these effects hold for other loci and readouts. We previously used a quantitative PCR method (quantitative CRISPR PCR, QC-PCR) to measure rates of deletion at the MALAT1 enhancer region 26 . For three out of four sgRNA pairs, we observed a significant enhancement of deletion with M3814 treatment of HeLa (Fig. 2c, note the inverted scale used for QC-PCR). Similar but weaker results were also observed for HCT116 (two out of four pairs) and HEK293T cells (one out of four pairs) ( Supplementary Fig. 3 ).
Together, these findings support the general applicability of DNA-PK inhibition independent of cell line or target regions.
DNA-PK inhibition in the context of high-throughput pooled screens
CRISPR-del perturbations can be employed in the context of pooled functional screens, where libraries of paired sgRNAs are delivered by lentivirus at low MOI, and the effect on phenotypes such as proliferation are recorded.
We asked whether DNA-PK inhibition is also practical under these conditions, by targeting the PLXND1 reporter with sgRNAs delivered by low-MOI lentivirus. In initial experiments, M3814 was added to cell media prior to lentiviral transduction, but no improvement in deletion efficiency was observed (data not shown). This is explained by the fact that lentiviruses require NHEJ for genomic integration 61, 62 . Therefore, we modified our protocol so as to leave sufficient time for viral integration before NHEJ inhibition (24 h was optimal, Supplementary Fig. 4 ), and observed a 2.7-fold increase in CRISPR-del efficiency (Fig. 2d ).
Pooled CRISPR screens employ phenotypic readouts, often in the form of cell proliferation 3, 27 . To test whether improved CRISPR-del translates into stronger phenotypes, we developed a reporter assay capable of quantifying the phenotypic effect of CRISPR-del in terms of cell death. Analagous to PLXND1 (Fig. 1a) , We designed three pairs of sgRNAs targeting the first exon of the essential gene, RPS5 (coding for the 40S ribosomal protein S5, P46782, Uniprot): RPS5-P+, P9, P10, P11. As expected, sgRNAs targeting the AAVS1 locus had no effect, while sgRNAs targeting the RPS5 ORF (RPS5-P+) resulted in ~47% mortality after 72 h ( Fig. 2e ). Neither was affected by M3814, indicating no toxicity. In contrast, three pairs of sgRNAs targeting the first exon of RPS5 (P9, P10, P11) resulted in a substantial mortality (32%, 21% and 15%, respectively), which was significantly enhanced by addition of M3814 (41%, 30% and 22%, respectively).
In conclusion, DNA-PK inhibition enhances CRISPR-del when sgRNAs are delivered lentivirally at low MOI, and results in increased downstream phenotypic effects, supporting its utility in the context of high-throughput pooled screens.
Discussion
The intrinsic DNA damage response underpins CRISPR-Cas9 genome editing and may be manipulated to favour desired editing outcomes. In the case of precise genome editing, which is based on the HDR pathway, efficiency has been substantially improved through pharmacological promotion of HDR and inhibition of the competing NHEJ pathway 37 . No such solutions have been developed for CRISPR-del, despite its being one of the most common CRISPR-Cas9 modalities, with diverse scientific and technological applications [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
We hypothesised that successful CRISPR-del requires paired DSBs to co-occur before NHEJ has time to act, and thus may be enhanced by pharmacological inhibition of DNA-PK. This is initially counter-intuitive, as DNA-PK is a necessary step in the NHEJ pathway upon which CRISPR-del relies, and its inhibition is widely used to promote HDR 37, 40, 44, 45 . However, rather than permanently blocking NHEJ, our protocol slows the kinetics of NHEJ for a defined period while DSBs are taking place. This produces a significant enhancement of DNA deletion efficiency, increasing protein knockout rates and resulting in stronger functional effects.
DNA-PK inhibition represents a practical option for a variety of CRISPR-del applications, from basic research to gene therapy. DNA-PK inhibitors are cheap and widely-available. Deletion efficiency improved regardless of the inhibitor molecule, target region, sgRNA sequence, cell background and delivery method. Particularly striking was the observation that some sgRNA pairs that are ineffective under normal conditions, achieved respectable rates of deletion using DNA-PK inhibition. This suggests that the failure of many sgRNA pairs to efficiently delete DNA arises not from their inability to promote DSBs, but rather as a result of poor kinetic properties (for example, a mismatch in kinetics between the two individual sgRNAs). Finally, this method (with minor modifications) is compatible with low-MOI lentiviral delivery and leads to improvements in observed cell phenotypes. These conditions are employed in pooled screens to probe the functions of non-protein coding genomic elements [18] [19] [20] [21] , meaning that DNA-PK inhibition may be used in future to improve the sensitivity of CRISPR-deletion screens by boosting the number of active sgRNA pairs, and their efficiency.
